MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY:LLY)

990.33 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EST, Mar 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
News headline image
1 Dividend Stock to Buy Hand Over Fist and 1 to Avoid ↗
Eli Lilly may be the GLP-1 leader, but its valuation is stretched. 
Via The Motley Fool
Topics Intellectual Property
News headline image
2 Unstoppable Dividend Stocks to Buy Right Now for Less Than $1,000 ↗
This Dividend King is out of favor, and this medical device peer has just introduced an exciting new product. 
Via The Motley Fool
News headline image
2 Underrated Weight Loss Stocks to Buy Now ↗
These companies have a lot more to offer than their prospects in the weight loss market. 
Via The Motley Fool
Topics Intellectual Property
Eli Lilly & Co (NYSE:LLY) Emerges as a Prime GARP Investment Candidate ↗
Via Chartmill
Eli Lilly & Co (NYSE:LLY): A High-Growth Dividend Stock for Discerning Investors ↗
Via Chartmill
News headline image
Where Will Eli Lilly Stock Be in 10 Years? ↗
Eli Lilly is at the head of the pharma pack today, but in a decade, the situation could look very different. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Can This Next-Gen Obesity Drug Save Novo Nordisk? ↗
Things can't get that much worse for the drugmaker. 
Via The Motley Fool
News headline image
Down but Not Out: Is Novo Nordisk a Conditional Buy as Eli Lilly Leads the GLP‑1 Market? ↗
Novo Nordisk looks cheap, but a rebound hinges on fixing execution and management credibility. 
Via The Motley Fool
News headline image
Tariffs News & Market Chaos ↗
President Trump's tariffs have been overturned, throwing the market into even more chaos in 2026. 
Via The Motley Fool
Topics Economy Government World Trade
News headline image
Here's How Much $1000 Invested In Eli Lilly 5 Years Ago Would Be Worth Today ↗
 
Via Benzinga
News headline image
HIMS Stock Rises Premarket: Investors Brush Off JPMorgan Stake Cut Amid FDA GLP-1 Crackdown ↗
The stake reduction comes as Hims navigates regulatory scrutiny over weight-loss drugs, while expanding into other healthcare categories. 
Via Stocktwits
Topics Earnings Lawsuit
News headline image
Novo Nordisk's Obesity Setback: What Kagrama's Miss vs. Zepbound Means for Investors ↗
Novo Nordisk's Kagrama stumbles versus Zepbound, forcing investors to reassess obesity‑drug expectations. 
Via The Motley Fool
News headline image
The Great Rotation: Why Global Capital is Deserting US Tech for International Value in 2026
As of early March 2026, the long-standing dominance of the S&P 500 (NYSEARCA: VOO) has met its most significant challenge in nearly a decade. For the first time since the mid-2010s, international... 
Via MarketMinute
Topics Artificial Intelligence ETFs Economy
News headline image
Renovations and Equipment Upgrades Fell 18% in February 2026; Other Capital Projects Remain Stable
JACKSONVILLE BEACH, Fla., March 5, 2026 (SEND2PRESS NEWSWIRE) -- Industrial SalesLeads released its February 2026 Planned Capital Project Spending Report for the Industrial Manufacturing sector. The... 
Via Send2Press
News headline image
Eli Lilly Targets Employer Coverage Gap With New Obesity Drug Access Platform ↗
Eli Lilly (NYSE: LLY) launches Employer Connect platform on March 5, 2026, offering Zepbound tirzepatide KwikPen at $449 across all doses to expand employer-sponsored obesity coverage. 
Via Benzinga
News headline image
Q4 Earnings Outperformers: Bristol-Myers Squibb (NYSE:BMY) And The Rest Of The Branded Pharmaceuticals Stocks
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
The Return of the Titans: M&A Volume Set to Surge 20% in 2026 Amidst "Animal Spirits"
As of March 4, 2026, the global financial landscape is witnessing a seismic shift in corporate strategy. After years of cautious maneuvering and high interest rates, the "animal spirits" of the... 
Via MarketMinute
Topics Artificial Intelligence Economy World Trade
News headline image
The Compounding Cliff: Hims & Hers Faces Reckoning as FDA and Big Pharma Close GLP-1 Loopholes
NEW YORK — The era of easy access to compounded weight-loss "knockoffs" is rapidly drawing to a close, leaving the telehealth industry’s once-shining star, Hims & Hers Health, Inc. (NYSE: HIMS), in a... 
Via MarketMinute
Topics Economy Intellectual Property Lawsuit
News headline image
S&P 500 to 7,800? Morgan Stanley Bets on "One Big Beautiful Act" and AI Productivity as Bears Warn of Bubble
As the first quarter of 2026 unfolds, the equity markets are at a historic crossroads. Morgan Stanley (NYSE:MS) has stunned Wall Street with a revised year-end target for the S&P 500, projecting the... 
Via MarketMinute
Topics Artificial Intelligence Economy Stocks
News headline image
Eli Lilly Unusual Options Activity For March 04 ↗
 
Via Benzinga
News headline image
Is Moderna Stock Outperforming the Dow?
Moderna has outperformed the Dow over the past year, yet Wall Street analysts maintain a cautious outlook on the stock’s prospects. 
Via Barchart.com
Topics Stocks
News headline image
Hims Stock Slips Overnight As FDA Warns Telehealth Firms Over GLP-1 Claims — Why Traders Think The ‘Overhang’ Won’t Last ↗
The warnings involve compounded versions of Semaglutide, Tirzepatide and Liraglutide, the active ingredients in Wegovy, Ozempic and Mounjaro. 
Via Stocktwits
Topics Lawsuit
News headline image
2 Top Growth Stocks to Buy in the First Half of 2026 ↗
A decade from now, you might be very glad you did so. 
Via The Motley Fool
News headline image
Should You Forget Eli Lilly and Buy These Unstoppable Stocks Instead? ↗
Lilly is leading the pack in the GLP-1 race, but this isn't a sprint, and you should consider more than just weight loss drugs. 
Via The Motley Fool
Topics Intellectual Property
News headline image
The Best Healthcare Stock to Invest $1,000 in Right Now ↗
There's nothing generic about this drugmaker's recent performance and continued prospects. 
Via The Motley Fool
News headline image
Buying This 1 Pharmaceutical Stock Today Could Make You a Multimillionaire Retiree ↗
This stock looks unstoppable right now. 
Via The Motley Fool
Topics Artificial Intelligence Intellectual Property
News headline image
Why I'm Not Worried About Novo Nordisk Stock ↗
The stock is down big of late, but the business is by no means doomed. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Up Over 400% in 5 Years, Is It Too Late to Invest in Eli Lilly Stock? ↗
Eli Lilly has been a growth beast in recent years, but its valuation has gotten fairly high along the way. 
Via The Motley Fool
News headline image
Should You Forget Eli Lilly and Buy This Magnificent High-Yield Dividend Stock Instead? ↗
Eli Lilly is making headlines in the pharmaceutical sector, but it's a very expensive stock. 
Via The Motley Fool
Topics Intellectual Property
News headline image
The Great Divergence: AI Supremacy Masks a Hidden Bear Market in Healthcare and Industrials
The final trading week of February 2026 has laid bare a striking fracture in the U.S. equity markets. While the technology sector continues to feast on a relentless AI-driven "execution" cycle, the... 
Via MarketMinute
Topics Artificial Intelligence Bonds Economy
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story